“Baxter is committed to partnering with healthcare professionals to foster continuous innovation in the ICU, which has been particularly critical throughout the COVID-19 pandemic,” said Reaz Rasul, general manager of Baxter’s Acute Therapies business told the press. “We are proud to provide industry-leading technologies and services through our PrisMax 2 system to help expand treatment possibilities by making CRRT and other extracorporeal organ support therapies more accessible.”
Developed based on direct feedback from clinicians and customers around the world, PrisMax 2 optimizes treatment accuracy, efficiency, and system performance. New advancements include system updates for improved visibility of critical information and simple, step-by-step onscreen instructions. PrisMax 2 also contains PrisMax’s innovative features, including an auto-effluent drain that reduces device interactions and decreases therapy downtime, and intelligent pump adjustments to help meet prescribed fluid removal targets and deliver more accurate treatments. Additionally, PrisMax 2 incorporates integrated safety features that combine preventive measures designed to reduce clinical risk and human error with smart alarms to alert users to respond to critical issues.
The PrisMax 2 system provides access to TrueVue digital health solutions to help enhance patient care and deliver value to hospitals. These include:
- TrueVue Connect, an optional add-on that simplifies and enhances secure wireless connectivity from PrisMax 2 to a hospital’s electronic medical records (EMR) system to help automate documentation of important treatment data. This helps ICU nurses spend less time on manual charting and focus more on patient care, which has been especially important as hospitals manage the COVID-19 pandemic. A recent survey found 77 percent of clinicians identify documenting and charting in the electronic health record as a source of cognitive overload,1 supporting the need for greater automation.
- TrueVue Therapy Management, a forthcoming, innovative consultative service offering where Baxter specialists will evaluate aggregated anonymized PrisMax 2 CRRT therapy data automatically captured by TrueVue Connect. Baxter specialists will then partner with hospitals to identify actionable insights that can help clinical teams optimize CRRT quality improvement programs, maximize resource utilization and deliver on their clinical goals.
The PrismaLung+ blood-gas exchanger can be used on PrisMax 2 to deliver ECCO2R therapy, which helps remove excessive CO2 in the bloodstream. This enables treatment of patients who may also require renal replacement therapy or other organ support therapies without increasing the complexity of delivery, staff training or requiring new capital expenditures. PrismaLung+ can deliver ECCO2R as a stand-alone therapy or in combination with CRRT simultaneously on one system with a single access point. Dedicated software provides step-by-step guidance for easy set-up and management of each therapy.